↓ Skip to main content

Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo‐controlled trial

Overview of attention for article published in Movement Disorders, March 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (84th percentile)
  • Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

news
1 news outlet
twitter
5 X users

Citations

dimensions_citation
52 Dimensions

Readers on

mendeley
172 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo‐controlled trial
Published in
Movement Disorders, March 2016
DOI 10.1002/mds.26617
Pubmed ID
Authors

Daniel Weintraub, Robert A. Hauser, Jordan J. Elm, Fernando Pagan, Matthew D. Davis, Azhar Choudhry, for the MODERATO Investigators

Abstract

This study's aims were to determine the efficacy and tolerability of rasagiline, a selective monoamine oxidase inhibitor B, for PD patients with mild cognitive impairment. Patients on stable dopaminergic therapy were randomized to adjunct rasagiline 1 mg/day or placebo in this 24-week, double-blind, placebo-controlled, multisite study. The primary endpoint was mean change from baseline to week 24 on the Scales for Outcomes of Parkinson's Disease-Cognition total score. Key secondary measures included changes in cognition, activities of daily living, motor scores, and Clinical Global Impression of Change, as well as safety and tolerability measures. Of the 170 patients randomized, 151 (88.2%) completed the study. Change in Scales for Outcomes of Parkinson's Disease-Cognition scores were not significantly different in the rasagiline and placebo groups (adjusted mean: 1.6 [standard error {SE} = 0.5] vs. 0.8 [SE = 0.5] points; LS means difference = 0.8; 95% confidence interval: -0.48, 2.05; P = 0.22). There were no between-group differences in change in the MoCA (p=0.84) or Penn Daily Activities Questionnaire (P = 0.48) scores or in the distribution of Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change modified for mild cognitive impairment (P = 0.1). Changes in motor (UPDRS part III; P = 0.02) and activities of daily living (UPDRS part II; P < 0.001) scores favored rasagiline. Rasagiline was well tolerated; the most common adverse events in both groups were falls and dizziness. Rasagiline treatment in PD patients with mild cognitive impairment was not associated with cognitive improvement. Rasagiline did not worsen cognition, improved motor symptoms and activities of daily living, and was well tolerated in elderly cognitively impaired patients. © 2016 International Parkinson and Movement Disorder Society.

X Demographics

X Demographics

The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 172 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 <1%
Unknown 171 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 22 13%
Student > Bachelor 19 11%
Researcher 18 10%
Student > Ph. D. Student 17 10%
Other 16 9%
Other 30 17%
Unknown 50 29%
Readers by discipline Count As %
Medicine and Dentistry 33 19%
Psychology 17 10%
Neuroscience 14 8%
Nursing and Health Professions 11 6%
Pharmacology, Toxicology and Pharmaceutical Science 10 6%
Other 31 18%
Unknown 56 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 April 2016.
All research outputs
#2,927,001
of 24,565,648 outputs
Outputs from Movement Disorders
#1,094
of 4,971 outputs
Outputs of similar age
#45,908
of 306,153 outputs
Outputs of similar age from Movement Disorders
#21
of 93 outputs
Altmetric has tracked 24,565,648 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,971 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.5. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 306,153 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 93 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.